VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Friday, January 2, 2026
Stock Comparison
AstraZeneca PLC vs The Charles Schwab Corporation
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
AstraZeneca PLC
AZN · London Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into AstraZeneca PLC's moat claims, evidence, and risks.
View AZN analysisThe Charles Schwab Corporation
SCHW · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into The Charles Schwab Corporation's moat claims, evidence, and risks.
View SCHW analysisComparison highlights
- Moat score gap: The Charles Schwab Corporation leads (74 / 100 vs 71 / 100 for AstraZeneca PLC).
- Segment focus: AstraZeneca PLC has 6 segments (41% in Oncology); The Charles Schwab Corporation has 2 segments (79.4% in Investor Services).
- Primary market structure: Oligopoly vs Oligopoly. Pricing power: Strong vs Weak.
- Moat breadth: AstraZeneca PLC has 4 moat types across 3 domains; The Charles Schwab Corporation has 7 across 4.
Primary market context
AstraZeneca PLC
Oncology
Innovator oncology therapeutics (branded prescription medicines)
Global
Hospitals, oncology clinics, payers
Innovator biopharmaceutical company
41%
The Charles Schwab Corporation
Investor Services
U.S. retail brokerage, self-directed investing, and wealth management platforms
United States
Retail investors, employers, retirement plan sponsors
Broker-dealer + bank + wealth manager platform
79.4%
Side-by-side metrics
Moat coverage
Shared moat types
AstraZeneca PLC strengths
The Charles Schwab Corporation strengths
Segment mix
AstraZeneca PLC segments
Full profile >Oncology
Oligopoly
Cardiovascular, Renal and Metabolism (CVRM)
Competitive
Respiratory & Immunology (R&I)
Oligopoly
Vaccines & Immune Therapies (V&I)
Oligopoly
Rare Disease
Oligopoly
Other Medicines
Competitive
The Charles Schwab Corporation segments
Full profile >Investor Services
Oligopoly
Advisor Services
Oligopoly
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.